Home » Exelixis Retains Right to Develop and Commercialize XL647
Exelixis Retains Right to Develop and Commercialize XL647
Exelixis, Inc. announced that GlaxoSmithKline (GSK) has decided not to exercise its option to license XL647 for further development and commercialization.
Biospace
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May